Topiramate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Topiramate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
333
Registered trials
130
Result records
4
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Topiramate can convert its Small molecule drug profile and AMPA receptor x CAs x GABAA receptor x VGSCs biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Topiramate (query alias: topiramate) |
|---|---|
| Modality / target | Small molecule drug; AMPA receptor x CAs x GABAA receptor x VGSCs; AMPA receptor antagonists, CAs inhibitors, GABAA receptor agonists |
| Highest global status | Approved |
| Originator | Janssen Global Services LLC |
| Active developers | Janssen Pharmaceuticals, Inc., Supernus Pharmaceuticals, Inc., Azurity Pharmaceuticals, Inc. |
The MCP disease footprint includes Seizures, Epilepsy, Migraine Disorders. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| ChiCTR2600127737 | Phase 3 | Not yet recruiting | 307 | The rate of achieving target serum uric acid ≤ 360 μmol/L (6.0 mg/dL) at Week 24 of treatment |
| NCT07384624 | Phase 1/2 | Not yet recruiting | 30 | Phase I primary outcome: Fold change in cell-associated HIV-RNA |
| NCT07588750 | Not Applicable | Not yet recruiting | 500 | Percent Change in Body Weight |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Treatment of Tinnitus With Migraine Medications: A Randomized Clinical Trial
Phase 4; n=78; evaluation: not stated. Reported fields: Tinnitus Functional Index (TFI)(Mean) = -6.0 scores on a scale (95% Confidence Interval, -12.935 to 0.916); Tinnitus Functional Index (TFI)(Mean) = -12.4 scores on a scale (95% Confidence Interval, -20.437 to -4.359); -
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of SPN-538 as a Therapy for the Prevention of Migraine in Subjects Ages 6-11 Years
Phase 4; n=26; evaluation: not stated. Reported fields: Titration Period 1 (Month 1)(Mean) = -2.89 monthly migraine days (Standard Deviation, 1.919); -; Titration Period 1 (Month 1)(Mean) = -3.08 monthly migraine days (Standard Deviation, 0.830)
High and Low Dose Topiramate for the Treatment of Alcohol-Dependent Smokers
Phase 2/3; n=236; evaluation: not stated. Reported fields: Continuous Smoking Abstinence in the Last 4 Weeks of Treatment Continuous Smoking Abstinence in the Last 4 Weeks of Treatment = 2 participants ; Continuous Smoking Abstinence in the Last 4 Weeks of Treatment Continuous Smoking Abstinence in the Last 4 Weeks of Treatment = 6 participants ; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Topiramate addresses Seizures, Epilepsy, Migraine Disorders. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2023-02-13 | Hyundai Pharmaceutical wishes to expand its central nervous system (CNS) focus by selling Janssen’s second-generation epilepsy treatment, Topamax | Approved | Financial terms not disclosed |
| Azurity Pharmaceuticals purchases Eton's neurology portfolio products, including ET-105, ET-104, and ET-101, for the treatment of epilepsy, partial seizures, and neurological disorders. | Not disclosed | US$15.0M upfront; US$30.0M milestones; US$45.0M stated total | |
| 2020-10-06 | Eton and Tulex collaborate to develop and produce ET-101 for the treatment of seizures and migraine. | NDA/BLA | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Topiramate liquid composition and its use, process to manufacture a composition and kit”. The milestone feed surfaced a patent-application signal described as “Cubosome based nasal spray of topiramate”. The milestone feed surfaced a patent-application signal described as “Stable pharmaceutical composition of topiramate”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
